Joshua Mason

Joshua Mason

Company: Mirati Therapeutics

Job title: Director - Medical Affairs Strategy


Targeting Tumors with KRAS G12C Mutations with Adagrasib (MRTX849): Current Status & Future Questions 10:00 am

History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C Clinical progress of KRAS G12C inhibitors (eg, adagrasib) in the clinic Future questions and directions for targeting KRAS G12CRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.